Paliperidona Teva (Paliperidone)

Paliperidone, the active ingredient in Paliperidona Teva, is an atypical antipsychotic presented as a tablet for oral use. It is prescribed for the treatment of schizophrenia and related psychotic disorders in adults. GNH USA supplies Paliperidona Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone is used in the management of psychotic disorders, primarily acting on dopamine and serotonin pathways. - Schizophrenia: reduces positive and negative symptoms and helps maintain stability. - Schizoaffective disorder: controls both mood and psychotic symptoms. - Maintenance treatment of schizophrenia: prevents relapse and recurrence of psychotic episodes.

Paliperidona Teva may cause a range of adverse reactions.

Common Side Effects: - Weight gain: increase in body mass index. - Somnolence: feeling unusually sleepy. - Akathisia: inner restlessness and urge to move. - Extrapyramidal symptoms: muscle stiffness or tremor. - Elevated prolactin: menstrual changes or galactorrhea. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity. - Tardive dyskinesia: persistent involuntary movements. - Severe orthostatic hypotension: marked drop in blood pressure on standing. - Seizures: convulsive episodes. - Agranulocytosis: dangerously low white‑blood‑cell count.

Before initiating therapy, clinicians should consider several safety measures. - Monitor weight: assess body weight regularly. - Check blood glucose: screen for hyperglycaemia. - Evaluate lipid profile: monitor cholesterol and triglycerides. - Observe for extrapyramidal symptoms: watch for movement disorders. - Measure prolactin levels: detect hormonal disturbances. - Store at room temperature: keep in the original pack, protect from moisture.

Paliperidona Teva can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase paliperidone exposure. - Potent CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - QT‑prolonging agents (e.g., certain antiarrhythmics): increase risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely):\n- CNS depressants (e.g., alcohol, benzodiazepines): enhance sedation. - Antihypertensive drugs: may exacerbate orthostatic hypotension. - Medications affecting prolactin (e.g., metoclopramide): can amplify hormonal side effects.